Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

There were no significant differences in baseline levels of 25(OH)D (p = 0.76), OC (p = 0.58), CTX (p = 0.68) and P1NP (p = 0.57) between those starting treatment with TDF: or non-TDF-containing regimens.

Source: Participants’ characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

HIV-uninfected healthy participants were also enrolled from the TNT-HIV 003 cohort which was established in 2012 to study the morbidity and mortality among both healthy HIV-infected and HIV-uninfected individuals from Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, and the Queen Savang Vadhana Memorial Hospital in Chonburi, Thailand.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study

Study design awaiting verification · PLoS ONE · 2020

Original publication title

Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study

Win Min Han; Lalita Wattanachanya; Tanakorn Apornpong; Jureeporn Jantrapakde; Anchalee Avihingsanon; Stephen J. Kerr; Nipat Teeratakulpisarn; Tanate Jadwattanakul; Tawatchai Chaiwatanarat; Patinut Buranasupkajorn; Reshmie Ramautarsing; Nittaya Phanuphak; Sarat Sunthornyothin; Kiat Ruxrungtham; Praphan Phanuphak; TNT 003.1 study team

© 2020 Han et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

There are limited data regarding long-term BMD changes over time among treatment-naïve people living with HIV (PLHIV) after initiating combined antiretroviral therapy (cART) in Asia. We aimed to study bone mineral density (BMD) changes among treatment-naïve PLHIV started treatment with tenofovir disoproxil fumarate (TDF): or non-TDF-containing regimen and HIV-uninfected controls in an Asian setting. The study was a five-year prospective study. BMD at lumbar spine (LS) (L1 to L4), total hip (TH), and femoral neck (FN) were measured by dual energy X-ray absorptiometry (DEXA) scans at baseline, months 12, 24 and 60.

Multivariate logistic regression models were used to explore factors associated with mean BMD ≥5% reduction after 5 years of cART. A total of 106 PLHIV (75 and 31 started TDF: and non-TDF-containing regimen, respectively) and 66 HIV-uninfected individuals were enrolled. The mean percent changes of BMD were significantly different longitudinally between TDF and non-TDF users (p<0.001 for LS, p = 0.006 for TH and p = 0.02 for FN). HIV-positive status and on TDF-containing regimen was independently associated with BMD loss ≥5% at month 60 (adjusted odds ratio [aOR] 7.0, 95% confidence interval [95%CI] 2.3 to 21.0, P = 0.001 for LS; aOR 4.9, 95%CI 1.7 to 14.3, P = 0.003 for TH and aOR 4.3, 95%CI 1.6 to 11.2, P = 0.003 for FN) compared to HIV-uninfected individuals.

In a multivariate model for PLHIV only, TDF use (vs. non-TDF, P = 0.005) and pre-treatment CD4+ count <350 cells/mm3 (vs. ≥350 cells/mm3, P = 0.02) were independently associated with ≥5% BMD loss in TH at month 60. Treatment-naïve PLHIV initiating treatment with TDF-containing regimen have higher BMD loss in a Thai cohort. TDF use and low pre-treatment CD4 count were independently associated with BMD loss at month 60 at TH. Earlier treatment initiation and interventions to prevent bone loss could improve skeletal health among PLHIV.

Clinicaltrials.gov: NCT01634607

Authors’ abstract

There are limited data regarding long-term BMD changes over time among treatment-naïve people living with HIV (PLHIV) after initiating combined antiretroviral therapy (cART) in Asia. We aimed to study bone mineral density (BMD) changes among treatment-naïve PLHIV started treatment with tenofovir disoproxil fumarate (TDF): or non-TDF-containing regimen and HIV-uninfected controls in an Asian setting. The study was a five-year prospective study. BMD at lumbar spine (LS) (L1 to L4), total hip (TH), and femoral neck (FN) were measured by dual energy X-ray absorptiometry (DEXA) scans at baseline, months 12, 24 and 60.

Multivariate logistic regression models were used to explore factors associated with mean BMD ≥5% reduction after 5 years of cART. A total of 106 PLHIV (75 and 31 started TDF: and non-TDF-containing regimen, respectively) and 66 HIV-uninfected individuals were enrolled. The mean percent changes of BMD were significantly different longitudinally between TDF and non-TDF users (p<0.001 for LS, p = 0.006 for TH and p = 0.02 for FN). HIV-positive status and on TDF-containing regimen was independently associated with BMD loss ≥5% at month 60 (adjusted odds ratio [aOR] 7.0, 95% confidence interval [95%CI] 2.3 to 21.0, P = 0.001 for LS; aOR 4.9, 95%CI 1.7 to 14.3, P = 0.003 for TH and aOR 4.3, 95%CI 1.6 to 11.2, P = 0.003 for FN) compared to HIV-uninfected individuals.

In a multivariate model for PLHIV only, TDF use (vs. non-TDF, P = 0.005) and pre-treatment CD4+ count <350 cells/mm3 (vs. ≥350 cells/mm3, P = 0.02) were independently associated with ≥5% BMD loss in TH at month 60. Treatment-naïve PLHIV initiating treatment with TDF-containing regimen have higher BMD loss in a Thai cohort. TDF use and low pre-treatment CD4 count were independently associated with BMD loss at month 60 at TH. Earlier treatment initiation and interventions to prevent bone loss could improve skeletal health among PLHIV.

Clinicaltrials.gov: NCT01634607

Publication and source details

Original title: Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study

Win Min Han; Lalita Wattanachanya; Tanakorn Apornpong; Jureeporn Jantrapakde; Anchalee Avihingsanon; Stephen J. Kerr; Nipat Teeratakulpisarn; Tanate Jadwattanakul; Tawatchai Chaiwatanarat; Patinut Buranasupkajorn; Reshmie Ramautarsing; Nittaya Phanuphak; Sarat Sunthornyothin; Kiat Ruxrungtham; Praphan Phanuphak; TNT 003.1 study team

PLoS ONE · 2020

Competing Interests: KR received honoraria or consultation fees from Merck, Roche, Jensen-Cilag, Johnson & Johnson, Mylan and GPO (Governmental pharmaceutical organization, Thailand); participated in a company sponsored speaker’s bureau from Abbott, Gilead, Bristol: Myers Squibb, Merck, Roche, Jensen-Cilag, ViiV Healthcare, and GPO (Governmental pharmaceutical organization); and received Chulalongkorn Academic Advancement into Its 2nd Century Project (CUAASC). AA has received honorarium for consultation from ViiV Healthcare. We confirm that the competing interests stated do not alter our adherence to PLOS ONE policies on sharing data and materials.

The rest of the authors declare no competing interests.

¶ Membership of the TNT 003.1 study team is listed in the Acknowledgments.

* E-mail: anchaleea2009@gmail.com
© 2020 Han et al2020Han et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ViiV HealthcareThai Red Cross AIDS Research Centre (TRC-ARC)Government research budget 2015 to 2016GRB_APS_12_58_30_09, GRB_APS_04_59_30_03Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn UniversityRA61/008This work was mainly supported by ViiV Healthcare; Thai Red Cross AIDS Research Centre (TRC-ARC); Government research budget 2015 to 2016 [grant number GRB_APS_12_58_30_09 and GRB_APS_04_59_30_03] and Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University [grant number RA61/008]. All of the sponsors had no role on the study design, data collection, data analysis and the writing of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T17:55:35.547699+00:00

DOI: 10.1371/journal.pone.0230368 · PMC7094833